FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253187833> ?p ?o ?g. }

• W4253187833 endingPage "30" @default.
• W4253187833 startingPage "22" @default.
• W4253187833 abstract "Objective: Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used to treat pain. The objective of this study was to compare the efficacies of celecoxib and ibuprofen for the treatment of acute pain. The null hypothesis was that no difference between celecoxib and ibuprofen exists. Methods: The study was a prospective, randomized, double-blind, controlled clinical trial. After consent, patients rated their pain on a 100-mm visual analog scale (VAS) and categorical intensity pain scale. Patients were then randomized to receive 200-mg or 400-mg celecoxib or 600-mg ibuprofen (all orally). Patients were contacted 5 hours after receiving study medication when a second VAS score was recorded, along with categorical pain intensity, pain relief score, side effects, and number of rescue medications taken. The main outcome measures were change in visual analog pain and categorical pain intensity scores, and pain relief scores, at five hours. Results: One hundred ten patients were evaluated and 105 were enrolled. Thirty-four received celecoxib 200 mg, 32 received celecoxib 400 mg, and 39 received ibuprofen 600 mg. Ninety-one were available for the five-hour VAS and 88 for the five-hour categorical pain intensity and pain relief analysis: The two patients who were unable to read a VAS were excluded, and two enrolled patients withdrew prior to medication. One patient was excluded because his injury was a fracture, and therefore did not meet the inclusion criteria. There was no statistical difference among the treatment groups in age, time from injury to medication, initial VAS score, percent lost to follow-up, or treatment with adjunctive therapy. There was no statistical difference in change of VAS among the groups at five hours: ibuprofen 600 mg (-23.8 mm [95% CI = -31.56 mm to -16.1 mm] [n = 32]), celecoxib 200 mg (-16.1 mm [95% CI = -24.3 mm to -7.98 mm] [n = 31]), and celecoxib 400 mg (-12.4 mm [95% CI = -23.1 mm to -1.8 mm] [n = 30]) (p = 0.16). There was no significant difference between the groups, at five hours, in change of categorical pain intensity (p = 0.11) or pain relief scores (p = 0.059), though the pain relief scale approached significance favoring ibuprofen. Conclusions: No significant difference exists among emergency department (ED) patients treated for acute pain, at five hours, with celecoxib 200 mg, celecoxib 400 mg, or ibuprofen 600 mg, though the power of the study to detect a change was low, 36%. However, the magnitude of pain relief for celecoxib, coupled with the cost of the medication, questions its use in the immediate ED setting." @default.
• W4253187833 created "2022-05-12" @default.
• W4253187833 creator A5010110652 @default.
• W4253187833 date "2003-01-01" @default.
• W4253187833 modified "2023-09-30" @default.
• W4253187833 title "A Randomized, Clinical Trial Comparing Oral Celecoxib 200 mg, Celecoxib 400 mg, and Ibuprofen 600 mg for Acute Pain" @default.
• W4253187833 doi "https://doi.org/10.1197/aemj.10.1.22" @default.
• W4253187833 hasPublicationYear "2003" @default.
• W4253187833 type Work @default.
• W4253187833 citedByCount "8" @default.
• W4253187833 countsByYear W42531878332013 @default.
• W4253187833 countsByYear W42531878332018 @default.
• W4253187833 countsByYear W42531878332019 @default.
• W4253187833 countsByYear W42531878332020 @default.
• W4253187833 crossrefType "journal-article" @default.
• W4253187833 hasAuthorship W4253187833A5010110652 @default.
• W4253187833 hasConcept C126322002 @default.
• W4253187833 hasConcept C14184104 @default.
• W4253187833 hasConcept C168563851 @default.
• W4253187833 hasConcept C2776467144 @default.
• W4253187833 hasConcept C2779944601 @default.
• W4253187833 hasConcept C42219234 @default.
• W4253187833 hasConcept C535046627 @default.
• W4253187833 hasConcept C71924100 @default.
• W4253187833 hasConcept C98274493 @default.
• W4253187833 hasConceptScore W4253187833C126322002 @default.
• W4253187833 hasConceptScore W4253187833C14184104 @default.
• W4253187833 hasConceptScore W4253187833C168563851 @default.
• W4253187833 hasConceptScore W4253187833C2776467144 @default.
• W4253187833 hasConceptScore W4253187833C2779944601 @default.
• W4253187833 hasConceptScore W4253187833C42219234 @default.
• W4253187833 hasConceptScore W4253187833C535046627 @default.
• W4253187833 hasConceptScore W4253187833C71924100 @default.
• W4253187833 hasConceptScore W4253187833C98274493 @default.
• W4253187833 hasIssue "1" @default.
• W4253187833 hasLocation W42531878331 @default.
• W4253187833 hasOpenAccess W4253187833 @default.
• W4253187833 hasPrimaryLocation W42531878331 @default.
• W4253187833 hasRelatedWork W15178828 @default.
• W4253187833 hasRelatedWork W1832583951 @default.
• W4253187833 hasRelatedWork W1998028259 @default.
• W4253187833 hasRelatedWork W2394592818 @default.
• W4253187833 hasRelatedWork W2739957692 @default.
• W4253187833 hasRelatedWork W2908796237 @default.
• W4253187833 hasRelatedWork W2921295182 @default.
• W4253187833 hasRelatedWork W3111769599 @default.
• W4253187833 hasRelatedWork W3176049800 @default.
• W4253187833 hasRelatedWork W2134208799 @default.
• W4253187833 hasVolume "10" @default.
• W4253187833 isParatext "false" @default.
• W4253187833 isRetracted "false" @default.
• W4253187833 workType "article" @default.